%0 Journal Article
%T Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
%A Malcolm Handel
%A Mustafa Acar
%A Prabhjot Juneja
%J Archive of "Open Access Rheumatology : Research and Reviews".
%D 2018
%R 10.2147/OARRR.S179704
%X To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic disease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines of treatment)
%K tumor necrosis factor inhibitors
%K arthritis
%K psoriatic
%K rheumatoid arthritis
%K ankylosing spondylitis
%K treatment persistence
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267492/